Filter by: patients
What is Niaspan ER?

This medicine is an antihyperlipidemic used to decrease levels of cholesterol and triglycerides in the blood.

Abbott's Niaspan ER site

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
High Cholesterol 10 3 Efficacy_moderate Efficacy_cant_tell
General health 3 0
Other 2 0
Increase effect of another treatment 2 0
Hypercholesterolemia 2 0
High triglycerides 2 1 Efficacy_cant_tell

See all 21 patients currently taking Niaspan ER

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
2
Moderate
2
Mild
0
None
2

Reported Dosages

  500 mg daily 1,000 daily 1,000 mg daily 1,500 mg daily 2,000 mg daily 3,000 mg daily
  3 Number of Patients: 3 1 Number of Patients: 1 9 Number of Patients: 9 4 Number of Patients: 4 3 Number of Patients: 3 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Niaspan ER (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice 2   Doctor's advice: 50%
Side effects too severe 2   Side effects too severe: 50%
Other 1   Other: 25%

See all 4 patients who’ve stopped taking Niaspan ER

Currently Taking Niaspan ER

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Niaspan ER

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Niaspan ER

Always
3 50%
Usually
2 33%
Sometimes
1 17%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Niaspan ER

Very
0 0%
Somewhat
1 17%
A little
0 0%
Not at all
5 83%

Cost

Paid out of pocket

Cost of Niaspan ER

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 25%
< $25
3 75%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 25, 2012.